A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
Phase 2
Completed
- Conditions
- Hormone Refractory Prostate CancerBone Metastases
- Registration Number
- NCT00156884
- Lead Sponsor
- Alberta Health services
- Brief Summary
This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.
- Detailed Description
This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 58
Inclusion Criteria
- adenocarcinoma of the prostate
- life expectancy > 3 months,
- symptomatic from bone metastases
- radiologic evidence of metastatic bone disease
- stable level of pain control
- >18 years
- ability to complete assessments
- prior treatment (chemo) > 4 weeks previous
- discontinued anti-androgens for > 4 weeks
Exclusion Criteria
- prior strontium therapy
- previous hemibody RT within 6 weeks
- previous cytotoxic chemotherapy within 4 weeks
- use of bisphosphonate medications within 4 weeks
- change in steroid dose within 4 weeks
- active uncontrolled infection
- impending or present spinal cord compression
- significant neurological disorder
- impending pathological fracture
- severe urinary incontinence
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Palliative pain response analgesic response
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
BC Cancer Agency
🇨🇦Vancouver, British Columbia, Canada
Tom Baker Cancer Centre
🇨🇦Calgary, Alberta, Canada